Basket Study (CT-100-002) to Evaluate the Effects of a DiNaMoâ„¢ Component Training (NCT05573685) | Clinical Trial Compass
CompletedNot Applicable
Basket Study (CT-100-002) to Evaluate the Effects of a DiNaMoâ„¢ Component Training
United States124 participantsStarted 2022-10-10
Plain-language summary
CT-100 is a platform that provides interactive, software based therapeutic components that may be used as part of a multimodal treatment in supplementary or standalone prescription or nonprescription software-based digital therapeutics (PDT/DTx), being developed by Click Therapeutics, Inc. (Click).
Who can participate
Age range18 Years – 65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Meets indication-specific eligibility criteria as reported by the study participant with adequate clinical documentation
* Self-reported average pain intensity during the last 7 days of ≥ 3 of 10 on the Numeric rating Scale (NRS scale) associated with the primary indication
* Fluent in written and spoken English (confirmed by ability to read and comprehend the informed consent form.)
* Willing and able to comply with study protocol and assessments, evidenced by completion of the Screening Survey.
* Lives in the United States.
* Has an active email address and is willing and able to receive email messages.
* Is the sole user of an iPhone with iPhone operating systems (iOS) 14 or later capabilities or a smartphone with an Android operating system (OS) 10 or later capabilities with cellular and/or internet access for the duration of the study period.
Exclusion Criteria:
* Has a comorbid acute pain condition, such as from current injuries
* Participation in a clinical trial (including psychotherapy, mindfulness, cognitive training, or drug treatment) within the last 2 months
* Initiation or change in primary disease-specific medication for 30 days prior to entering the study
* Self-reported substance use disorder within the past 1 year
* Daily use of opioids of 30 MME (Morphine Milligram Equivalents) or more
* Substance use disorder within the past 1 year.
* Initiation or change in central nervous system-active medication (e.g., antidepressants) during th…
What they're measuring
1
To estimate the effect size for changes in pain experience (interference) in the Treatment App group compared to the Digital Control App group